Phathom Pharmaceuticals (PHAT) Accounts Payables (2018 - 2026)

Phathom Pharmaceuticals (PHAT) has 9 years of Accounts Payables data on file, last reported at $6.4 million in Q1 2026.

• On a quarterly basis, Accounts Payables fell 45.21% year-over-year to $6.4 million in Q1 2026; TTM through Mar 2026 was $6.4 million, a 45.21% decrease from a year earlier, with the FY2025 full-year figure at $5.0 million, down 52.57% from the prior year.
• Accounts Payables for Q1 2026 stood at $6.4 million, up from $5.0 million in the prior quarter.
• Over the last five years, Accounts Payables for PHAT reached as high as $12.6 million in Q4 2023 and fell as low as $1.1 million in Q3 2025.
• Historically, Accounts Payables has averaged $6.8 million across 5 years, with a median of $6.4 million in 2026.
• Across the five-year window, Accounts Payables jumped 94.12% in 2022 and sank 84.93% in 2025, its largest moves.
• Year by year, Accounts Payables stood at $10.0 million in 2022, then climbed by 26.05% to $12.6 million in 2023, then decreased by 16.62% to $10.5 million in 2024, then plunged by 52.57% to $5.0 million in 2025, then gained by 27.73% to $6.4 million in 2026.
• Per Business Quant data, the three most recent Accounts Payables figures were $6.4 million in Q1 2026, $5.0 million in Q4 2025, and $1.1 million in Q3 2025.